Category: Trick or Trade

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.   Why This is Important By remaining inactive until activated by the cancers’ microenvironment’s proteases, the Probody therapeutics minimizes the active drug’s toxicity …
An Evaluation of Biotech Firms Part 4

An Evaluation of Biotech Firms Part 4

A Comprehensive Essay  Part 4 Our fair evaluation approaches of biotechnology and biopharma companies differ depending on the sizes and statuses of the firms. We reiterate our conviction that causing a selloff of development stage biotech stocks at every announcement of quarterly financial results because of lack of income is irrelevant and unfair to the firms and their stockholders. It does not make sense that …
Why Moderna Therapeutics’ Stock Is Down Today

Why Moderna Therapeutics’ Stock Is Down Today

Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin with, most, if not all, development-stage firms are yo-yo games played by day traders and investors whose strategies are buying low and selling high. These people also buy and sell on encouraging news and bad news; if their eyes happen to fall on any fundamental news.   One of …
An Evaluation of Biotech Firms Part 3

An Evaluation of Biotech Firms Part 3

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex (VRTX) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a matter of fact, we use the histories of real firms in this essay for the sake of demonstrating the above without considering the Companies’ technologies or approved …
An Evaluation of Biotech Firms Part 2

An Evaluation of Biotech Firms Part 2

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex remains our case in point. In Part 1 we acknowledged that we picked VRTX on March 18, 2011 at $44.39. The question is: …
An Evaluation of Biotech Firms Part 1

An Evaluation of Biotech Firms Part 1

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked stocks which proved to be highly successful after being condemned by erroneous evaluations from unfair analysts. Some of these firms faced problems that are not unusual for drug designing and developing firms. While trying to overcome their obstacles, the firms in question were faced with unfortunate debilitating attacks by …